Enterome raises $11.5M for gut microbiome R&D

Paris-based Enterome Bioscience, focused on the gut microbiome, has raised €10 million ($11.5 million) in the first tranche of its Series B fundraising. Seventure (including from its new Health for Life Capital fund), Lundbeckfond Ventures and Omnes Capital contributed cash to the deal. "With these new funds we will be able make further significant progress towards our goal of developing new disease management solutions that will provide important benefits to patients suffering from conditions where the gut microbiome plays a key role," CEO Pierre Belichard said in a statement. Release